Critical Markers of Disease
home contact us  

2005 Cardiovascular Biomarkers and Surrogate Endpoints Symposium

Bethesda, Maryland
September 23-24, 2005

2005 Overview

2005 Agenda

2005 Faculty

As a service to our meeting attendees, the following presentation materials are available for viewing. Please note that material availability is at the discretion of our participating faculty.

If you've installed Windows SP 2, please allow your browser to show active content to view these files.

*Login Required to View Materials - Symposium Registrants will receive a username and password at the time of registration

  1. Welcome and Conference Objectives - Dr. Jean-Claude Tardif and Dr. Therese Heinonen
  2. Pathogenesis of Atherothrombotic Disease and Biomarker Identification - Dr. Peter Libby
  3. Is CRP a Validated Biomarker of CV Disease? - Dr. Paul Ridker
  4. The Role of Imaging in Disease Detection and Treatment - Dr. Jean-Claude Tardif
  5. Markers of Aging and Dementia - Dr. Lewis Kuller
  6. The Need for Biomarkers in Drug Development - Dr. Bill Sasiela
  7. The FDA Critical Path Initiative - Opportunities and Challenges - Dr. Douglas Throckmorton
  8. How Does the FDA Metabolism and Endocrine Department View Surrogate Endpoints? - Dr. David Orloff
  9. The role of Lipoproteins in Inflammation - Dr. Philip Barter
  10. Oxidation in the Pathogenesis of Atherosclerosis - Dr. Jay Heinecke
  11. Special Considerations in Diabetes and Metabolic Syndrome - Dr. Steven Haffner
  12. Opportunities for the use of Biomarkers and Surrogate endpoints in the European Union - Dr. Eric Abadie
  13. The Balance Between Safety and Efficacy: Biomarkers as Safety Surrogates - Dr. Eric Brass
  14. Diagnostic and Therapeutic Synergies - Dr. Donald Black
  15. Current Status of Disease Assessment with Carotid Ultrasound - Dr. Allen Taylor
  16. IVUS As a Surrogate Endpoint - Dr. Steve Nissen
  17. Palpography and Elastography as Biomarkers of Cardiovascular Disease - Dr. Ton van der Steen
  18. Advances in Cardiovascular Imaging - Dr. Minh Nguyen
  19. Combined Blood Biomarkers: Diminishing Returns or are More Better - Dr. Wolfgang Koenig
  20. Applying Genomics, Proteomics and Metabolomics Technology to Development Programs -
    Dr. Michael Phillips
"Building partnerships that lead to innovation and better patient outcomes."
International Partnership for Critical Markers of Disease
PO Box 132200 • Ann Arbor, MI 48113
Phone: 734.929.2095
Powered by AlliedMedia.net

Critical Markers of Disease Critical Markers of Disease Critical Markers of Disease